Compare Bilibili Inc (BILI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs BIO-TECHNE Corp — how do they compare? Bilibili Inc trades at $18 (market cap $7.71B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BILI | TECH | |
|---|---|---|
Market Cap | $7.71B | $11.24B |
Sector | Media | Health |
52-Week High | $35.92 | $72.29 |
52-Week Low | $15.96 | $43.31 |
Enterprise Value | $5.54B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $18.74, up 0.48% with neutral technical signals. The company reported strong Q1 2026 earnings of $0.19 per share, beating estimates, and maintains solid profitability with a 4.58% net margin. Recent news highlights a new $300 million share repurchase program and upcoming Q2 2026 results on August 27, 2026. Technical indicators show mixed signals with RSI neutral but moving averages bullish.
Bilibili presents a compelling investment case with consistent earnings beats and strong analyst support (83% buy ratings). However, risks include competitive pressures in China's video platform market and reliance on advertising revenue growth. The upcoming Q2 earnings report will be crucial for validating the company's monetization strategy and user engagement metrics.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
